Saurabh Upadhyay

Dr. Saurabh Upadhyay

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2025 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
KUKirti Upmanyu
Kirti Upmanyu
SUSaurabh Upadhyay
Saurabh Upadhyay

13 March 2025 in Biochemistry
Verified
Journal Article
Closed access
SUSaurabh Upadhyay
Saurabh Upadhyay
MBMohit Bhardwaj
Mohit Bhardwaj
SKSivakumar Prasanth Kumar
Sivakumar Prasanth Kumar
SKShumayila Khan
Shumayila Khan
AKAshwani Kumar
Ashwani Kumar
Md. Imtaiyaz HassanMd. Imtaiyaz Hassan
Md. Imtaiyaz Hassan

12 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SKShumayila Khan
Shumayila Khan
SUSaurabh Upadhyay
Saurabh Upadhyay
SKSana Kauser
Sana Kauser
GHGULAM MUSTAFA HASAN
GULAM MUSTAFA HASAN
WLWenying Lu
Wenying Lu
Sukhwinder SohalSukhwinder Sohal
Sukhwinder Sohal
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality globally, driven by marked molecular and cellular heterogeneity that complicates diagnosis and treatment. Despite advances in targeted therapies and immunotherapies, treatment resistance frequently emerges, and clinical benefits remain limited to specific molecular subtypes. To improve early detection and dynamic monitoring, novel diagnostic strategies—including liquid biopsy, low-dose computed tomography scans (CT) with radiomic analysis, and AI-integrated multi-modal platforms—are under active investigation. Non-invasive sampling of exhaled breath, saliva, and sputum, and high-throughput profiling of peripheral T-cell receptors and immune signatures offer promising, patient-friendly biomarker sources. In parallel, multi-omic technologies such as single-cell sequencing, spatial transcriptomics, and proteomics are providing granular insights into tumor evolution and immune interactions. The integration of these data with real-world clinical evidence and machine learning is refining predictive models and enabling more adaptive treatment strategies. Emerging therapeutic modalities—including antibody–drug conjugates, bispecific antibodies, and cancer vaccines—further expand the therapeutic landscape. This review synthesizes recent advances in NSCLC diagnostics and treatment, outlines key challenges, and highlights future directions to improve long-term outcomes. These advancements collectively improve personalized and effective management of NSCLC, offering hope for better-quality survival. Continued research and integration of cutting-edge technologies will be crucial to overcoming current challenges and achieving long-term clinical success.

2 December 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SJSungwoo Jo
Sungwoo Jo
FGFarida El Gaamouch
Farida El Gaamouch
SUSaurabh Upadhyay
Saurabh Upadhyay
HNHossam Nada
Hossam Nada
KKKatarzyna Kuncewicz
Katarzyna Kuncewicz
Moustafa GabrMoustafa Gabr
Moustafa Gabr
Triggering receptor expressed on myeloid cells 2 (TREM2) dysfunction contributes to Alzheimer's disease pathogenesis, yet current therapeutics cannot prevent ADAM-mediated receptor shedding that diminishes signaling efficacy. Using Affinity Selection-Mass Spectrometry (AS-MS) screening, we identified As48, a novel small molecule that binds TREM2 with high affinity. Biophysical validation confirmed 7-fold selectivity over TREM1. Cellular assays demonstrated that As48 functions as a TREM2 agonist, activating SYK phosphorylation and enhancing microglial phagocytosis. Molecular docking and molecular dynamics simulations revealed that As48 binds near the cleavage region, establishing hydrogen bonds with Gly68 and reducing conformational flexibility in regions 58-102. Based on this structural insight, we investigated the effect of As48 on TREM2 ectodomain shedding and discovered inhibition of receptor shedding without affecting ADAM10/17 protease activities, representing the first small molecule with anti-shedding properties through conformational restriction of protease accessibility. Importantly, As48 displayed favorable pharmacokinetics with potential for brain permeability, supporting its translational relevance. Through its dual and simultaneous promotion of receptor activation and prevention of shedding, As48 represents a paradigm shift in TREM2 modulation and neuroinflammatory drug discovery.

18 October 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SKShumayila Khan
Shumayila Khan
SUSaurabh Upadhyay
Saurabh Upadhyay
Md. Imtaiyaz HassanMd. Imtaiyaz Hassan
Md. Imtaiyaz Hassan

3 March 2026 in Genes & Immunity
Verified
Journal Article
Closed access
PDF file
MBMohit Bhardwaj
Mohit Bhardwaj
KUKirti Upmanyu
Kirti Upmanyu
SUSaurabh Upadhyay
Saurabh Upadhyay